C. Frank Bennett
0000-0001-9887-6251
Publication & Citation Trends
Publications
0 total
Personalized antisense oligonucleotides ‘for free, for life’ — the n-Lorem Foundation
Cited by 27
Semantic Scholar
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.
Cited by 31
Semantic Scholar
GOLGA8 increases bulk antisense oligonucleotide uptake and activity in mammalian cells. OA
Cited by 7
Semantic Scholar
Long-Term SMN- and Ncald-ASO Combinatorial Therapy in SMA Mice and NCALD-ASO Treatment in hiPSC-Derived Motor Neurons Show Protective Effects OA
Cited by 9
Semantic Scholar
Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies OA
Cited by 157
Semantic Scholar
Antisense drugs for rare and ultra-rare genetic neurological diseases. OA
Cited by 14
Semantic Scholar
Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1 OA
Cited by 37
Semantic Scholar
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial OA
Cited by 127
Semantic Scholar
Research Topics
Neurogenetic and Muscular Disorders Research
(73)
RNA Interference and Gene Delivery
(69)
RNA Research and Splicing
(67)
RNA modifications and cancer
(52)
DNA and Nucleic Acid Chemistry
(49)
Affiliations
Università Cattolica del Sacro Cuore
University of the Sciences
Regulus Therapeutics (United States)
Allegheny College
Boston Children's Hospital